Homepage
White Paper: Strategies to Accelerate the Development of ADCs
In our latest white paper, we discuss challenges in addressing antibody-drug conjugate design, resistance mechanisms, safety assessment, and PK/PD studies.
Integrated Direct-to-Biology (D2B) Platform
Learn how our D2B platform can streamline iterative design-synthesis-test cycles by directly testing high-throughput synthesized compounds in biological assays
Video: Key Steps in Validating Targeted Protein Degraders
Learn about our comprehensive discovery platform to support research on the complete functional cycle of targeted protein degraders
WuXi Biology
A full spectrum of biology services and solutions, supporting stand-alone and integrated projects, from target discovery to candidate selection and into the clinic
Enabling Unbounded Possibilities
WuXi Biology provides a full spectrum of services and solutions to support stand-alone and integrated projects, from target discovery to candidate selection and into the clinic. Our world-class discovery platform is backed by nearly 3000 scientists, offering expertise in all major disease areas and target classes, across all therapeutic modalities. From small molecules, oligonucleotides, and peptides to antibodies, cell, and gene therapies, our state-of-the-art services, fast turnaround times, and quick study launches meet the diverse needs of our clients.
Speak with a SpecialistTarget Discovery to Candidate Selection and Beyond
Supporting stand-alone and integrated projects
Comprehensive platform from target ID to drug candidates
Target Identification and Validation
Finding druggable targets
Comprehensive coverage of target classes and therapeutic modalities
Hit Identification
Screening services to accelerate drug discovery
Integrated platform with diverse methods to identify hit compounds
Hit Validation and Early Optimization
Confirming chemistry tractability
In vitro screening platform to support medicinal chemistry
Lead Discovery Services
Enhancing the most promising compounds
In vivo services to accelerate drug discovery
Preclinical Drug Development
Enabling the selection of the best candidates
Integrated platform for preclinical R&D to accelerate timelines
Investigational New Drug Discovery
Comprehensive IND enabling testing platform
Supporting clients from research to market
Latest Science
Latest White Paper
Strategies to Accelerate the Development of Antibody-Drug Conjugates
Strategies to Accelerate the Development of Antibody-Drug Conjugates
VIEW White PaperLatest Poster
Development of Rodent Models for Diabetic Neuropathy
Development of Rodent Models for Diabetic Neuropathy
VIEW PosterLatest Poster
STZ-Induced Diabetic Retinopathy Models
STZ-Induced Diabetic Retinopathy Models
VIEW PosterOvercoming PARP Inhibitor Resistance in an Olaparib-Induced Model
VIEW PosterEffects of Incretin-Based Therapies on Metabolic and Muscular Homeostasis
VIEW PosterTargeting MC4R with Setmelanotide Improves Metabolic Parameters in DIO Mice
VIEW PosterTargeting the CB1 Receptor for Enhanced Obesity Management
VIEW PosterLatest Publication
Native Mass Spectrometry Facilitates Validation of DEL Hits
Native Mass Spectrometry Facilitates Validation of DEL Hits
VIEW PublicationLatest Publication
Discovery of a Novel CD39 Inhibitor by DEL...
Discovery of a Novel CD39 Inhibitor by DEL Screening
VIEW PublicationSevere Hyperglycemia and Hyperlipidemia Alter Tumor Growth and Immune Profiles
VIEW Poster